Juventas Cell Therapy Ltd.

China’s cell therapy market will grow into an exclusive space for domestic companies, at least over the coming years, after Gilead Sciences, Inc. on 13 September divested through Kite Pharma, Inc.

Chinese immuno-oncology specialist CARsgen Therapeutics and Huadong Medicine Co., Ltd. , its domestic commercialization partner, on 1 March won regulatory approval in China for zevorcabtagene autol

According to the latest National New Drug Approval Report for 2023 from China's National Medical Products Administration (NMPA), 15 orphan drugs were approved through the regulator's designated priori

Amylyx Pharmaceuticals, Inc. announced Phase II/III results for AMX0035 in the treatment of amyotrophic lateral sclerosis (ALS) last year and hoped to obtain US Food and Drug Administration approval